stockrowAbbott Laboratories
ABT Healthcare Medical Devices
Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.
- Revenue
- +14.5%
- EPS
- −43.6%
- Free cash flow
- +28.9%
- Total debt
- +140.8%
Quarter to September 2026, against a year earlier
Follow ABT
Alert me
Abbott Laboratories (ABT) Total debt
Abbott Laboratories's total debt at the end of fiscal 2025 was $12.9B, down 8.47% from $14.1B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $31.2B. Over the past ten years it has ranged from $5.9B (fiscal 2015) to $27.7B (fiscal 2017); the current reading is higher than 18% of that period. Abbott Laboratories ranks 1st of 147 Medical Devices companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $12.9B | (8.47%) |
| FY2024 | $14.1B | (3.77%) |
| FY2023 | $14.7B | (12.48%) |
| FY2022 | $16.8B | (7.07%) |
| FY2021 | $18.1B | (2.61%) |
| FY2020 | $18.5B | 3.32% |
| FY2019 | $17.9B | (7.37%) |
| FY2018 | $19.4B | (30.13%) |
| FY2017 | $27.7B | 34.01% |
| FY2016 | $20.7B | 252.13% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $31.2B | (4.44%) |
| Jun 2026 | $32.6B | (4.23%) |
| Mar 2026 | $34.0B | 163.34% |
| Dec 2025 | $12.9B | (0.09%) |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ABT Abbott Laboratories | $32.6B |
| MDT Medtronic PLC compare | $28.2B |
| SYK Stryker Corporation compare | $14.9B |
| BSX Boston Scientific Corporation compare | $12.0B |
| GEHC GE HealthCare Technologies Inc. compare | $11.6B |
| PHG Koninklijke Philips N.V. compare | $8.0B |
| STE STERIS plc compare | $1.9B |
| DXCM DexCom, Inc. compare | $1.2B |
| EW Edwards Lifesciences Corporation compare | $598.8M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ABT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement